Sarah Hinkle, NP
Nurse Practitioner · Newark, DENPI 1659744845
Payments from drug & device makers
Across 45 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$170
- UCB, Inc.$163
- AbbVie$145
- Abbott$142
- Neurocrine Biosciences, Inc.$136
- Amneal Pharmaceuticals LLC$115
- plus $347 from 9 others
What the payments were for
- Food & beverage$1,10791%
- Education$1119%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $170 |
| UCB, Inc. | 5 | $163 |
| AbbVie(2 entities) | 7 | $145 |
| Abbott | 1 | $142 |
| Neurocrine Biosciences, Inc. | 3 | $136 |
| Amneal Pharmaceuticals LLC | 5 | $115 |
| Jazz Pharmaceuticals Inc. | 4 | $86 |
| Sunovion Pharmaceuticals Inc. | 4 | $65 |
| Sumitomo Pharma America, Inc. | 4 | $47 |
| Kyowa Kirin, Inc. | 2 | $46 |
| MDD US Operations, LLC | 1 | $31 |
| Livanova USA, Inc. | 1 | $23 |
| Medtronic | 1 | $21 |
| Acorda Therapeutics, Inc | 1 | $14 |
| Cala Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFINITY$142
How this compares
$1,219 in reported general payments places this provider in the 80th percentile of 487 nurse practitioner providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 77 | $392,569 |
| Droxidopa | 67 | $354,432 |
| IngrezzaValbenazine Tosylate | 40 | $323,194 |
| AustedoDeutetrabenazine | 41 | $315,804 |
| RytaryCarbidopa/Levodopa | 98 | $205,051 |
| Austedo XrDeutetrabenazine | 22 | $148,418 |
| GocovriAmantadine Hcl | 13 | $107,226 |
| XcopriCenobamate | 65 | $104,094 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 595 | $35,096 |
| NeuproRotigotine | 31 | $31,584 |
| Topiramate ErTopiramate | 15 | $25,776 |
| Lacosamide | 143 | $24,949 |
| NayzilamMidazolam | 22 | $17,852 |
| AptiomEslicarbazepine Acetate | 14 | $16,756 |
| Lamotrigine ErLamotrigine | 36 | $14,344 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $170 | $464,22163 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $136 | $336,74651 claims |
| Amneal Pharmaceuticals LLCRytary | $115 | $205,05198 claims |
| MDD US Operations, LLCGocovri | $31 | $107,22613 claims |
| UCB, Inc.Neupro, Nayzilam | $163 | $49,43653 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $65 | $16,75614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Newark
- Sedelle Henderson-BamideleNewark$13K
- Funmilola OlaoyeNewark$7K
- Lyron DeputyNewark$6K
- Mark LandisNewark$5K
- Noreen Murphy BowensNewark$4K
- Mary ZimnyNewark$4K
- Amanda WardwellNewark$4K
- Heather DennisNewark$4K
- Anesha VictorNewark$3K
- Lori GrantNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.